471 related articles for article (PubMed ID: 17164371)
1. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor.
Chen C; Freeman R; Voigt LF; Fitzpatrick A; Plymate SR; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2461-6. PubMed ID: 17164371
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
Chokkalingam AP; McGlynn KA; Gao YT; Pollak M; Deng J; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
Cancer Res; 2001 Jun; 61(11):4333-6. PubMed ID: 11389055
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study.
Canzian F; McKay JD; Cleveland RJ; Dossus L; Biessy C; Boillot C; Rinaldi S; Llewellyn M; Chajès V; Clavel-Chapelon F; Téhard B; Chang-Claude J; Linseisen J; Lahmann PH; Pischon T; Trichopoulos D; Trichopoulou A; Zilis D; Palli D; Tumino R; Vineis P; Berrino F; Bueno-de-Mesquita HB; van Gils CH; Peeters PH; Pera G; Barricarte A; Chirlaque MD; Quirós JR; Larrañaga N; Martínez-García C; Allen NE; Key TJ; Bingham SA; Khaw KT; Slimani N; Norat T; Riboli E; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2316-25. PubMed ID: 16214911
[TBL] [Abstract][Full Text] [Related]
6. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
Spitz MR; Barnett MJ; Goodman GE; Thornquist MD; Wu X; Pollak M
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1413-8. PubMed ID: 12433720
[TBL] [Abstract][Full Text] [Related]
8. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
Safarinejad MR; Shafiei N; Safarinejad S
Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
[TBL] [Abstract][Full Text] [Related]
9. No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer.
Li L; Cicek MS; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):497-8. PubMed ID: 15006930
[No Abstract] [Full Text] [Related]
10. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
[TBL] [Abstract][Full Text] [Related]
11. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
[TBL] [Abstract][Full Text] [Related]
12. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels.
Diorio C; Brisson J; Bérubé S; Pollak M
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):880-8. PubMed ID: 18398029
[TBL] [Abstract][Full Text] [Related]
14. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women.
Ren Z; Cai Q; Shu XO; Cai H; Li C; Yu H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1290-5. PubMed ID: 15298948
[TBL] [Abstract][Full Text] [Related]
17. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women.
Jernström H; Deal C; Wilkin F; Chu W; Tao Y; Majeed N; Hudson T; Narod SA; Pollak M
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):377-84. PubMed ID: 11319179
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
[TBL] [Abstract][Full Text] [Related]
19. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
20. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
